1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Celltrion, Inc.
  6. News
  7. Summary
    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
End-of-day quote Korea Stock Exchange  -  05-19
145000.00 KRW   +2.84%
05/18Celltrion, Inc. authorizes a Buyback Plan.
CI
05/17Celltrion, Inc. announces an Equity Buyback for 500,000 shares.
CI
05/16Celltrion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Three South Korean Firms to Manufacture Low-Cost Variants of Merck's COVID-19 Pill

01/21/2022 | 06:01am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
CELLTRION, INC. 2.84% 145000 End-of-day quote.-26.77%
HANMI PHARM. CO., LTD. 2.04% 300500 End-of-day quote.8.88%
KOSPI COMPOSITE INDEX 0.20% 2643.92 Real-time Quote.-11.35%
All news about CELLTRION, INC.
05/18Celltrion, Inc. authorizes a Buyback Plan.
CI
05/17Celltrion, Inc. announces an Equity Buyback for 500,000 shares.
CI
05/16Celltrion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/12Celltrion's Net Profit Falls 39.2% in Q1; Shares Slip 6%
MT
04/28Celltrion To Enter U.S. Humira Biosimilar Market Following Patent Agreement With AbbVie
AQ
04/19Celltrion's CT-P6 Demonstrates Equivalent Safety, Efficacy With HERCEPTIN
AQ
04/18Celltrion Healthcare Starts Selling Chronic Inflammatory Disease Biosimilar Yuflyma in ..
MT
04/07Regeneron's Disclaimer Of Aflibercept Formulation Patent Causes PTAB Denial Of Institut..
AQ
04/05Celltrion Announces Agreement With Brazilian Government To Supply Infliximab Biosimilar
AQ
04/01Regeneron Disclaims An Aflibercept Formulation Patent In Response To Celltrion PGR
AQ
More news
Analyst Recommendations on CELLTRION, INC.
More recommendations
Financials
Sales 2022 2 145 B 1,68 B 1,68 B
Net income 2022 569 B 0,45 B 0,45 B
Net cash 2022 996 B 0,78 B 0,78 B
P/E ratio 2022 34,1x
Yield 2022 0,17%
Capitalization 20 047 B 15 744 M 15 744 M
EV / Sales 2022 8,88x
EV / Sales 2023 8,00x
Nbr of Employees 2 034
Free-Float 75,2%
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLTRION, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 145 000,00 KRW
Average target price 194 520,50 KRW
Spread / Average Target 34,2%
EPS Revisions
Managers and Directors
Wu-Sung Ki Chief Executive Officer & Director
Ho-Seop Lee Finance Director
Jung-Jin Seo Chairman
Sung-Han Lee Head-Legal & Compliance Support
Dong-Il Kim Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CELLTRION, INC.-26.77%15 744
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567